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Abstract.
Background: The ongoing COVID-19 pandemic has many consequences for people with Parkinson’s disease (PD). Social
distancing measures complicate regular care and result in lifestyle changes, which may indirectly cause psychological stress
and worsening of PD symptoms.
Objective: To assess whether the COVID-19 pandemic was associated with increased psychological distress and decreased
physical activity in PD, how these changes related to PD motor and non-motor symptom severity, and what frequency and
burden of COVID-related stressors were.
Methods: We sent an online survey to the Personalized Parkinson Project (PPP) cohort (n = 498 PD patients) in the Nether-
lands. In the survey, we distinguished between COVID-related stressor load, psychological distress, PD symptom severity,
and physical activity. We related inter-individual differences to personality factors and clinical factors collected before the
pandemic occurred.
Results: 358 PD patients completed the survey between April 21 and May 25, 2020 (response rate 71.9%). Patients with higher
COVID-related stressor load experienced more PD symptoms, and this effect was mediated by the degree of psychological
distress. 46.6% of PD patients were less physically active since the COVID-19 pandemic, and reduced physical activity
correlated with worse PD symptoms. Symptoms that worsened most were rigidity, fatigue, tremor, pain and concentration.
Presence of neuropsychiatric symptoms (anxiety, depression) before the pandemic, as well as cognitive dysfunction and
several personality traits predicted increased psychological distress during the COVID-19 pandemic.
Conclusion: Our findings show how an external stressor (the COVID-19 pandemic) leads to a worsening of PD symptoms
by evoking psychological distress as well as lifestyle changes (reduced physical activity).
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INTRODUCTION
The ongoing COVID-19 pandemic has an enor-
mous impact on the physical as well as mental
well-being of citizens across the world. Individuals
who might have had contact with the SARS-CoV-2
virus are requested to isolate themselves. In addition,
many countries have introduced different degrees
of social distancing rules, including working from
home, avoiding physical contact, closure of schools
and restaurants, and travel restrictions.
As such, the COVID-19 pandemic has severely dis-
rupted the lives of many people worldwide. Indeed,
during earlier virus outbreak situations, many people
reported psychological distress extending beyond the
outbreak period [1], which underlines the importance
of psychological care in susceptible individuals [2].
Importantly, the consequences reach even further in
persons living with a chronic disease [3], and Parkin-
son’s disease (PD) is a prime example of this. The
pandemic has markedly affected PD in several ways.
First, although the risk of becoming infected is not
increased for PD patients compared to the general
population [4], those who do contract a SARS-CoV-
2 infection are likely to experience a worsening of
their symptoms [5]. It is not entirely clear whether the
mortality is increased for PD patients with COVID-
19, but patients with long-standing disease and those
receiving an advanced treatment may well have a
higher risk of dying [6]. Second, the care for PD
patients has changed [7]: surgical treatments have
been postponed [8], and access to outpatient clinics
has been limited to prevent the spread of COVID-19
[9], making routine physical assessment and medica-
tion adjustments in non-emergency situations more
difficult. Third, the social, economic, and medical
consequences of the pandemic have led to profound
lifestyle changes in PD patients, such as a reduced
overall physical activity, inability to participate in
exercise classes and increased levels of psycholog-
ical distress. In PD, these lifestyle changes have been
referred to as the “hidden sorrows” of the COVID-
19 pandemic [10] since these may indirectly cause
a worsening of symptoms: physical activity attenu-
ates PD motor symptoms [11], so being grounded
at home is particularly deleterious for this popula-
tion; and psychological distress worsens a variety of
motor symptoms [12, 13] and also induces or aggra-
vates neuropsychiatric symptoms such as anxiety and
depression [14].
The primary objective of this study was to test the
hypothesis that the COVID-19 pandemic has led to an
increased psychological distress in PD, thereby wors-
ening PD symptoms. To this end, we distinguished
between direct and indirect COVID-related stressors
(such as respiratory symptoms, media coverage, or
degree of social isolation) and perceived stress (psy-
chological distress). This distinction is important: a
similar set of stressors may lead to psychological dis-
tress in one patient but not in the other. Our second
objective was to evaluate COVID-related changes in
physical activities in PD, and to test whether this cor-
related with a worsening of PD symptoms. Third,
we explored which stressors were most frequently
encountered and most burdensome for patients, and
which PD symptoms were affected most. Finally, we
aimed to identify predictors of (increased) psycholog-
ical distress in PD patients during the pandemic. This
may help to identify vulnerable PD patients that could
benefit from extra care in future crises, for example by
offering telemedicine services [15, 16]. To test these
predictions, we developed a focused online survey in
an existing, well-defined longitudinal cohort of PD




A survey invitation was sent to all participants of
the PPP, which currently consists of 498 PD patients.
PPP is a single-center, longitudinal observational
study with an observation period of two years, with
three annual assessments at the Radboud university
medical center in Nijmegen, the Netherlands [17].
All patients in the PPP had a disease duration of
≤5 years at inclusion. Measurements included exten-
sive clinical assessments (including motor, cognitive
and psychological tests), collection of biospecimens
(stools, whole blood, and cerebrospinal fluid) and
3T MRI brain imaging. Subjects gave informed con-
sent electronically to participate in this additional
COVID-19 survey study.
Timeline
Figure 1 shows the timeline of important events
and measures taken by the Dutch government since
the first confirmed COVID-19 case in the Netherlands
on February 27, 2020. In addition, the survey time-
line is visualized. On April 15, participants of the
PPP cohort were asked to participate in the additional
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Fig. 1. Timeline: The relationship between the number of initially reported COVID-19 related deaths and measures taken in response. Also
shown is the timeline of the baseline survey acquisition which is reported in the current article. WHO, World Health Organization; CBS, the
Dutch ‘Central Bureau of Statistics’.
COVID-19 survey study, for which approval was
granted by the local medical ethical committee (file
number 2016-2934). From April 21 onwards, after
governmental measures had been in place for several
weeks, the baseline survey was sent to all people who
had given informed consent.
Survey content
The survey content partly overlapped with an
ongoing global survey (DynaCORE-C, http://www.
dynacore.info) assessing psychological resilience to
the mental health consequences of the COVID-19
pandemic in healthy subjects, but our survey also con-
tained PD-specific items. We distinguished between
perceived stress, PD symptom severity, stressor load,
physical activity and personality factors. Specifi-
cally, the Perceived Stress Scale (PSS) [18] was
our measure of perceived stress (i.e., psychological
distress): it evaluates how unpredictable, uncon-
trollable and overloading someone experienced the
previous month, and their perceived ability to cope.
We assessed PD symptom severity with the self-
assessment part of the Unified Parkinson’s Disease
Rating Scale part Ib and II (MDS-UPDRS-self) [19].
In addition, we added the subscale of the Parkin-
son Anxiety Scale (PAS) [20] measuring episodic
anxiety and the brooding subscale of the Rumi-
native Response Scale (RRS) [21]. We also asked
participants to rate to what extent PD symptoms
were different in severity at this moment compared
to the month preceding the start of the COVID-
19 pandemic, on a 9-point scale (1 = much worse,
5 = no change, 9 = much improved) and evaluated
self-reported changes in physical activity and min-
utes/hours of (moderate) intensive exercise per week.
Next, we added a list of 18 potential external stres-
sors asked participants which stressors of these they
had been exposed to and if so, how burdensome
they experienced this. Most of these stressors were
related to changes due to the COVID-19 pandemic.
Elements that we copied from DynaCORE-C were
the SOZU-K-10 on perceived social support [22], the
Brief Resilience Scale [23], the neuroticism subscale
of the Big Five Inventory 10 [24], a selection of 10
items from the brief COPE [25] and 12 items from
the Cognitive Emotion Regulation Questionnaire
(CERQ) [26]. These selected items of COPE and
CERQ were used to generate two measures: positive
appraisal and behavioral coping. Positive appraisal
avoids catastrophizing, pessimism and unnecessar-
ily low self-efficacy or control perceptions, but at the
same time avoids unrealistically positive (delusional)
threat perceptions [27]. Behavioral coping assesses
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typical thinking processes that people perform when
they are challenged.
Statistical analysis
Data were loaded into IBM SPSS Statistics 23
to calculate sum-scores for the validated scales and
to perform statistical testing. Positive appraisal and
behavioral coping were calculated as described by
Veer et al. (2020) [28]: positive appraisal included
the average of all 12 CERQ item scores and the
2 humor sub scores of COPE, for behavioral cop-
ing we took the average of the remaining 8 COPE
items [28]. First, we conducted Pearson correlation
analyses among cumulative stressor load, PSS and
MDS-UPDRS-self, prior to performing a mediation
analysis. Our hypothesis that PSS mediates the asso-
ciation between stressor load and symptom severity
was tested using the PROCESS macro developed by
Hayes (2013) [29], in which the 95% confidence
interval of the indirect effects was obtained with
5,000 bootstrap samples. With a one-sample t-test
we tested whether change in physical activity was
significant different from 5 (no change). Change
in physical activity was correlated with change in
PD symptom severity and PSS scores using Spear-
man correlations, in which change in PD symptom
severity was calculated as the average change score
across all symptoms combined for every participant.
We also assessed changes in separate PD symptoms
since the COVID-19 pandemic, by merging responses
into 3 classes: worsening (scores 1–4), no change
(score 5) and improvement (scores 6–9). With a one-
sample t-test we assessed whether change in PD
symptom severity was significantly different from 5
(no change), and we calculated Pearson correlations
with perceived stress (PSS) and symptom severity
(MDS-UPDRS-self). We quantified stressor load by
evaluating which stressors (from a list of 18) par-
ticipants had been frequently exposed to, and which
were most burdensome. We subsequently quanti-
fied individual cumulative stressor load by weighing
each reported stressor by its burden rating (1–5)
and formed a weighted sum. Additional correlations
between PSS and hypothesized protective person-
ality traits, clinical characteristics and stressor load
were again calculated with Pearson correlations, and
we corrected for multiple comparisons. Given the
exploratory nature of this analysis, we corrected for
multiple comparisons (n = 17) using a conservative
Bonferroni correction (i.e., p < 0.0029 was consid-
ered significant).
Data handling and data availability
We used Castor (https://data.castoredc.com) to
collect survey data. All data were stored with poly-
morphic encryptions and pseudonyms (PEP), to
guarantee the privacy of participants but also to
enable data sharing with interested researchers. This
system allows qualified researchers to have access to
the entire dataset or a subset of the dataset with spe-




On April 15, 2020, all 498 enrolled PPP partici-
pants were invited to participate in this COVID-19
study (Table 1). 358 of them (response rate = 71.9%)
completed the baseline survey (38.5% women), with
a mean age of 62.8 years and a mean disease dura-
tion of 3.9 years. Table 1 also shows the general
characteristics and total scores of the scales col-
lected during the most recent PPP visit, which was
on average 7.5 months prior to the COVID-survey,
well before the start of the COVID-pandemic in the
Netherlands. For these scales, non-responders scored
higher on anxiety (STAI), depression (BDI), sleep-
ing problems (SCOPA-sleep), motor and non-motor
symptoms and aspects of experiences of daily living
(MDS-UPDRS-I and MDS-UPDRS-II), and slightly
lower on cognitive abilities (MoCA).
Impact on psychological distress and PD
symptom severity
Higher stressor load was associated with higher
scores on perceived stress (PSS) (R = 0.34, [95% CI
0.25, 0.43]), and MDS-UPDRS-self symptom sever-
ity (R = 0.26, [95% CI 0.16, 0.35]) (Fig. 2A). More
specifically, the positive relationship between stressor
load and increased PD symptom severity was medi-
ated by increased levels of perceived stress (PSS;
Fig. 2B): cumulative stressor load was a significant
predictor of PD symptom severity (b = 0.208 [95%
CI 0.127, 0.289]), but this relationship was no longer
significant in the presence of the standardized indi-
rect effect (b = 0.171*0.866 = 0.148 [95% CI 0.094,
0.206]) of perceived stress as a mediator in the model
(b = 0.061 [95% CI –0.013, 0.134]).
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Table 1
Characteristics of the study population
General characteristics Responders (n = 358) Non-responders (n = 140) Difference
Mean (SD) or n (%) Mean (SD) or n (%)
Age (years) 62.8 (9.0) 63.3 (9.1) p = 0.890
Gender (% women) 138 (38.5%) 62 (44.3%) p = 0.351
Disease duration (years) 3.9 (1.8) 4.3 (2.0) p = 0.059
Use of dopaminergic medication (% yes) 93.9% 97.9% p = 0.060
Presence of other medical conditions (% yes) 67.3% 66.4% p = 0.849
Assessment at last PPP visit (on average 7.5 months prior to COVID-19 survey)
Unified Parkinson’s Disease Rating Scale
MDS-UPDRS I 12.0 (5.4) 13.6 (5.7) p = 0.003*
MDS-UPDRS II 8.3 (5.9) 9.8 (6.8) p = 0.024*
MDS-UPDRS self-assessment (Ib + II) 17.7 (8.5) 20.4 (9.5) p = 0.003*
MDS-UPDRS III On PD medication 29.5 (12.6) 30.9 (12.5) p = 0.234
MDS-UPDRS III Off PD medication 34.8 (12.9) 35.0 (13.7) p = 0.675
Hoehn & Yahr On state Off state On state Off state On state
1 14 (3.9%) 15 (4.2%) 6 (4.3%) 6 (4.3%) p = 0.520
2 311 (86.9%) 308 (86.0%) 120 (85.7%) 117 (83.6%) Off state
3 9 (2.5%) 30 (8.4%) 8 (5.7%) 13 (9.3%) p = 0.940
4 4 (1.1%) 45(1.4%) 2 (1.4%) 3 (2.1%)
Missing 20 (5.6%) 0 (0%) 4 (2.9%) 1 (0.7%)
Montreal Cognitive Assessment (MoCA) 26.8 (2.4) 26.0 (3.4) p = 0.003*
State Trait Anxiety Inventory (STAI) 70.8 (18.1) 79.4 (21.8) p = 0.000*
Beck’s Depression Inventory II (BDI-II) 9.9 (6.3) 12.6 (7.7) p = 0.000*
Scales for Outcomes in PD (SCOPA-sleep) 7.6 (5.0) 8.9 (5.6) p = 0.020*
Years of education 12.9 (2.7) 12.9 (2.8) p = 0.893
Living situation
With partner 64.8% 65.7% p = 0.642
With family 24.3% 20.3%
Alone 7.5% 9.1%
Other 3.4% 4.9%
Paid job (% yes) 39.1% 35.0% p = 0.388
Assessment during COVID-19 survey (on average 1.4 months after introduction of social distancing measures)
MDS-UPDRS self-assessment (Ib+II) 16.5 (9.4)
Social Support (SOZU-K) 31.4 (5.1)
Brief Resilience Scale (BRS) 3.5 (0.7)
Optimism (5-point scale) 4.0 (0.8)
Positive appraisal style (CERQ & COPE) 11.9 (2.6)
Behavioral coping style (CERQ & COPE) 20.1 (4.2)
Perceived Stress Scale (PSS) 9.9 (5.8)
Parkinson Anxiety Scale (PAS part B) 5.8 (2.0)
Ruminative Response Scale (RRS) 1.9 (2.0)
Neuroticism (BFI-neuroticism) 4.9 (1.9)
Mean (SD) or number (percentages) for demographic and clinical characteristics, and total scores of the scales used in our COVID-19 survey.
Column 3 shows the p-values for differences between non-responders and responders, for continuous variables measured with t-tests and
for categorical variables with χ2-tests. We indicated all significant differences of p < 0.05 with *.
Impact on physical activity
Patients were significantly less active than before
the pandemic when comparing against a score
of 5 (no change): (MD = –0.50, [95% CI –0.67,
–0.33]). Specifically, 46.6% of responders were less
active compared to before the pandemic, 33.0%
were equally active and 20.4% were more active.
Patients with lower scores on this 9-point scale (i.e.,
less physical activity) experienced more worsening
of PD symptoms (rs = 0.14 [95% CI 0.03, 0.25]).
Furthermore, 38.8% of patients were physically
active ≥4 hours per week. There was no relation-
ship between time spent on physical activity and the
degree of perceived stress (PSS) (rs = –0.08 [95% CI
–0.18 0.05]).
Changes in PD symptoms
Figure 3 shows subjective changes in PD symp-
tom severity during the COVID-19 pandemic, as
compared to the month before the pandemic started.
The average individual score of all 13 evaluated
PD symptoms significantly worsened during the
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Fig. 2. Relationship between stressor load, psychological distress, and PD symptom severity (A) The positive linear relationships between
the three factors of the mediation analysis. (B) The standardized regression coefficients for the relationship between cumulative stressor load
(total of experienced COVID-related stressors weighted by the experienced burden; range = 0–71) and self-assessed symptom severity (sum
of MDS-UPDRS Ib and MSD-UPDRS II score; range = 2–53) as mediated by perceived stress (PSS score; range = 0–28) The direct effect
is indicated by c’, the indirect effect by a*b, the total effect by c (*p < 0.001).
Fig. 3. Change in PD symptom severity during COVID-19 pandemic. Changes in PD symptom severity of 13 problems which are common
in PD during the COVID-19 pandemic, as compared to a month before the pandemic started (n = 358). The colored boxplots show responses
on the 9-point scale (1 = much worse, 5 = no change, 9 = much improved). The percentages at the right side of the boxplots show percentages
of people that experienced worsening (scores of 1–4), no change (scores of 5) and improvement (scores of 6–9) for every of these symptoms.
Symptoms are ordered by how much they got worse during the COVID-19 pandemic.
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COVID-19 pandemic, when compared against a
score of 5 (no change): (MD = –0.36, [95% CI –0.43,
–0.29]). Patients with higher levels of perceived stress
(PSS) experienced more worsening of PD symptoms
(R = –0.37, [95% CI –0.46, –0.28]). Furthermore,
patients with more severe PD symptoms (MDS-
UPDRS-self) experienced more worsening of their
symptoms during the pandemic (R = –0.46, [95% CI
–0.54, –0.37]). Symptoms for which most worsening
was perceived were rigidity, fatigue, tremor, pain and
concentration.
Stressor exposure
Stressors that were most frequently experienced
by PD patients were loss of social contact (93.1%),
COVID-19 related media coverage (91.7%), not
being able to perform physical activity or leisure
activities as usual (78.7%) and feeling restricted to
leave home (75.6%). Most burdensome (scale 1–5)
for PD patients were not being able to attend the
funeral of a loved one (3.6), being restricted in visiting
loved ones in the hospital (3.4), loss of social contact
(3.1) and not being able to perform physical activi-
ties or leisure activities as usual (3.0). An overview
of all stressors can be found in the Supplementary
Material.
Predictors of psychological distress
Table 2 shows an overview of personality
traits, clinical characteristics, and stressor load,
and how these factors correlate to perceived stress
(PSS) scores. In addition to the effects described
above (Fig. 2), people with high perceived stress
scores (PSS) had lower scores on social support,
trait resilience, optimism, positive appraisal style,
whereas they scored higher on anxiety, rumination
and neuroticism (Table 2). We did not find a sig-
nificant association (Bonferroni corrected) with age,
disease duration, sex, time of physical activity, cog-
nitive abilities or behavioral coping style.
DISCUSSION
We report the results of the COVID-survey assess-
ing the impact of the COVID-19 crisis in a large
group of 358 PD patients, for whom we also had
longitudinal baseline findings spanning the period
prior to the pandemic. There are four main findings.
First, patients with higher COVID-related stressor
load experienced higher PD symptom severity, and
this effect was mediated by the degree of psycho-
logical distress [30]. Second, 46.6% of PD patients
in our sample were physically less active since the
COVID-19 pandemic unfolded, and the reduction in
physical activity correlated with worsening of PD
symptoms. Third, we showed that the symptoms
that worsened most were rigidity, fatigue, tremor,
pain and concentration. Fourth, we found that PD
patients with high perceived stress levels experi-
enced more anxiety, rumination and neuroticism, and
they scored lower on cognitive abilities, social sup-
port, trait resilience, optimism and positive appraisal
style.
Our findings fit with a recent study in a much
smaller group of 38 Egyptian PD patients, who
reported higher levels of stress and anxiety during the
pandemic than healthy controls, as well as reduced
physical exercise [31]. Here we extend these previ-
ous findings by showing that physical activity and
psychological distress increased symptom severity
in the patients. Surprisingly, time of physical activ-
ity and perceived stress were not correlated to each
other, despite some reports showing that physical
activity lowers stress [32]. This may suggest that
both lifestyle factors independently influence disease
severity through different mechanisms and, conse-
quently, that both should be targeted separately as part
of a comprehensive treatment approach. Symptoms
for which most PD patients experienced worsening
were rigidity, fatigue, tremor and pain. The subjec-
tive increase in tremor and rigidity is in line with
previous work showing that these symptoms are par-
ticularly sensitive to stress [12, 33]. Increased pain
may similarly result from increased anxiety but could
also be secondary to rigidity; this remains speculative.
Fatigue is a well-known consequence of psycholog-
ical distress [34, 35], also in non-PD populations.
Dyskinesias increased only in 13.1% and gait diffi-
culties in 24.6% of PD patients, which seems low
when considering previous studies which showed
that psychological distress clearly worsens these two
symptoms [13, 36]. This may be explained by the
fact that our sample consisted of relatively early
PD patients (disease duration of 3.9 years), where
these symptoms are relatively uncommon. The fact
that even these relatively mildly affected patients
were already affected substantially underscores the
enormous impact of the COVID-19 pandemic; we
suspect that the consequences are even greater in
more severely affected patients with longstanding
disease.
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Table 2
Associations between psychological distress (PSS) and hypothesized resilience factors
Hypothesized factors influencing psychological Correlation with psychological distress (PSS)
distress Pearson’s R [95% CI] P-value
General characteristics
Age (years) R = –0.01 [95% CI –0.12 0.09] p = 0.809
Biological sex R = –0.04 [95% CI –0.14 0.06] p = 0.451
Physical activity (minutes per week) R = –0.07 [95% CI –0.17 0.04] p = 0.195
Clinical characteristics
PD disease duration (years) R = 0.01 [95% CI –0.09, 0.11] p = 0.825
PD symptom severity in daily life (MDS-UPDRS Ib + II) R = 0.57 [95% CI 0.50 0.64] p = 0.000
Anxiety
Parkinson Anxiety Scale (PAS part B) R = 0.62 [95% CI 0.55, 0.68] p = 0.000
State-Trait Anxiety Inventory (STAI)1 R = 0.64 [95% CI 0.56, 0.69] p = 0.000
Ruminative Response Scale (RRS) R = 0.57 [95% CI 0.50, 0.64] p = 0.000
Cognitive abilities (MoCA)1 R = –0.14 [95% CI –0.24 –0.04] p = 0.007
Depression (BDI-II)1 R = 0.51 [95% CI 0.43, 0.58] p = 0.000
Sleeping problems (SCOPA-sleep)1 R = 0.30 [95% CI 0.20, 0.39] p = 0.000
Stressor load
Cumulative stressor load R = 0.34 [95% CI 0.25, 0.43] p = 0.000
Personality traits
Perceived social support (SOZU-K) R = –0.32 [95% CI –0.41, –0.22] p = 0.000
Brief Resilience Scale (BRS) R = –0.56 [95% CI –0.63, –0.48] p = 0.000
Optimism (5-point scale) R = –0.36 [95% CI –0.45, –0.27] p = 0.000
Neuroticism (BFI-neuroticism) R = 0.52 [95% CI 0.44, 0.59] p = 0.000
Positive appraisal style (CERQ & COPE) R = –0.31 [95% CI –0.40, –0.21] p = 0.000
Behavioral coping style (CERQ & COPE) R =–0.10 [95% CI –0.20, 0.00] p = 0.068
Bold values significant correlations at p < 0.05 (p < 0.0029 after Bonferroni correction). 1 measurement at last PPP assessment on average 7.5
months before the COVID-19 survey, not added in the survey. Pearson correlation values and their confidence intervals between psychological
distress (score on Perceived Stress Scale (PSS)) and several general and clinical characteristics, stressor load and personality traits.
The COVID-19 related stressor that was most fre-
quently experienced (by 93.9% of patients) was loss
of social contacts. This is in line with recent inter-
views with German PD patients, 86.9% of whom
reported having fewer social contacts and staying at
home more because of the COVID-19 pandemic [37].
Others mentioned that due to their PD, they already
had a low number of social contacts or were fre-
quently homebound. The greatest fear amongst the
interviewed German patients was becoming infected
with COVID-19. This was different in our sample:
even among the 19% of patients who experienced
COVID-19 related symptoms, this was not experi-
enced as burdensome (2.6 on a scale of 1–5). Healthy
respondents to the DynaCORE survey resembled our
PD sample regarding the most frequently experienced
and most burdensome stressors. One striking differ-
ence is that 22.6% of patients were unable to attend
the funeral of a loved one, whereas this was only
11.1% in the DynaCORE respondents. Another dif-
ference is that as many as 56.4% of our PD group
belonged to a risk group for a serious disease course
in case of a COVID-19 infection (average burden 2.5),
and this was the case for 33.3% of the DynaCORE
respondents (average burden 3.0).
The most vulnerable patients in our study, i.e.,
those with the highest levels of psychological distress,
were people with lower baseline cognitive abilities
and increased neuropsychiatric symptoms at baseline
(i.e., collected before the COVID-19 pandemic), as
well as low (perceived) social support and specific
personality characteristics such as low trait resilience,
low optimism, and high neuroticism. This is in line
with previous studies in healthy people [28, 38, 39].
Longitudinal follow-up of our cohort might reveal
which factors remain correlated with changes in psy-
chological distress over time. Some of these factors
can possibly be addressed in vulnerable PD patients
throughout a developing crisis, e.g., through individ-
ual remote counseling, or by distributing self-help
material via social media.
When interpreting these effects, the specific sam-
ple that we investigated should be considered. The
response rate (71.9%) was very high, but interest-
ingly, the non-responders had higher baseline scores
on anxiety, depression, subjective severity of PD
symptoms, and lower cognitive abilities. In our anal-
yses (Table 2), these factors predicted increased
perceived stress, suggesting that our findings may be
an underestimation of perceived stress in the entire
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PD population. This notion is further strengthened
by the fact that our sample had relatively mild PD,
given the inclusion criteria of the PPP (disease dura-
tion <5 years at inclusion). We acknowledge that the
lack of a control group does not allow us to determine
to what extent our findings are specific to PD. Indeed,
as we outlined above, some of the observed effects,
such as the relationship between personality charac-
teristics and perceived stress, may generalize to the
whole population. On the other hand, our primary
findings concern the relationship with PD symptoms,
for which a control group is not necessary.
Strengths of the current study are the large PD sam-
ple for which many baseline measures were collected
prior to this present COVID-19 survey. Additionally,
we were able to make a clear distinction between indi-
vidual stressor load on the one hand and perceived
stress or psychological distress on the other. How-
ever, there are some limitations regarding the degree
to which these results can be generalized to all PD
patients. First, the PPP cohort consists of patients with
relatively early-stage PD. The impact of COVID-
19 might well be even more dramatic for patients
with late-stage PD. Second, due to the retrospective
nature of the survey, responses might be less accu-
rate, since for most questions we had no baseline data
for the period from before the COVID-19 pandemic.
Moreover, the correlations we found do not imply
causality. The hypothesized protective personality
traits for which we found relatively high correla-
tions with psychological distress might be trained
or strengthened in vulnerable PD patients, but they
cannot be used to clinically identify which people
will develop mental problems. Finally, stressor load
should ideally be based on a more extensive list of
(non-COVID related) items, although we already see
strong correlations with other measures when using
only the current items.
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